These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36865283)

  • 1. Investigating genetic overlap between antidepressant and lithium response and treatment resistance in major depressive disorder.
    Lu Y; Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigstrom R; Jonsson L; Clements C; Andersson E; Boberg J; Lewis C; Sullivan P; Landén M
    Res Sq; 2023 Feb; ():. PubMed ID: 36865283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
    Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigström R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landén M; Lu Y
    Transl Psychiatry; 2023 Sep; 13(1):301. PubMed ID: 37770441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts.
    Fabbri C; Hagenaars SP; John C; Williams AT; Shrine N; Moles L; Hanscombe KB; Serretti A; Shepherd DJ; Free RC; Wain LV; Tobin MD; Lewis CM
    Mol Psychiatry; 2021 Jul; 26(7):3363-3373. PubMed ID: 33753889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression.
    Zhdanava M; Karkare S; Pilon D; Joshi K; Rossi C; Morrison L; Sheehan J; Lefebvre P; Lopena O; Citrome L
    Adv Ther; 2021 Sep; 38(9):4900-4916. PubMed ID: 34368919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder.
    Gronemann FH; Petersen J; Alulis S; Jensen KJ; Riise J; Ankarfeldt MZ; Solem EJ; Bødker N; Osler M
    J Affect Disord; 2021 May; 287():204-213. PubMed ID: 33799039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of treatment resistance on outcome and course of electroconvulsive therapy in major depressive disorder.
    Rovers JJE; Vissers P; Loef D; van Waarde JA; Verdijk JPAJ; Broekman BFP; Vergouwen ACM; Oudega ML; van Exel E; Coenen R; Everaerd DS; Tendolkar I; Dols A; van Eijndhoven PFP
    Acta Psychiatr Scand; 2023 Jun; 147(6):570-580. PubMed ID: 37020420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment resistant depression: actuality and perspectives in 2017].
    Lucas N; Hubain P; Loas G; Jurysta F
    Rev Med Brux; 2017; 38(1):16-25. PubMed ID: 28525197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
    Tundo A; de Filippis R; Proietti L
    World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Correlates of Treatment-Resistant Depression: Insights from Polygenic Scores Across Cognitive, Temperamental, and Sleep Traits in the All of US cohort.
    Xu B; Forthman KL; Kuplicki R; Ahern J; Loughnan R; Naber F; Thompson WK; Nemeroff CB; Paulus MP; Fan CC
    medRxiv; 2024 Jul; ():. PubMed ID: 39006419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits.
    Kang J; Castro VM; Ripperger M; Venkatesh S; Burstein D; Linnér RK; Rocha DB; Hu Y; Wilimitis D; Morley T; Han L; Kim RY; Feng YA; Ge T; Heckers S; Voloudakis G; Chabris C; Roussos P; McCoy TH; Walsh CG; Perlis RH; Ruderfer DM
    Am J Psychiatry; 2024 Jul; 181(7):608-619. PubMed ID: 38745458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study.
    Lähteenvuo M; Taipale H; Tanskanen A; Rannanpää S; Tiihonen J
    J Affect Disord; 2022 Jul; 308():236-242. PubMed ID: 35398108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.
    Réus GZ; de Moura AB; Borba LA; Abelaira HM; Quevedo J
    Mol Neuropsychiatry; 2019 Oct; 5(4):178-189. PubMed ID: 31768371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact of treatment-resistant depression: A retrospective observational study.
    Pérez-Sola V; Roca M; Alonso J; Gabilondo A; Hernando T; Sicras-Mainar A; Sicras-Navarro A; Herrera B; Vieta E
    J Affect Disord; 2021 Dec; 295():578-586. PubMed ID: 34509073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine.
    Garakani A
    J Psychiatr Pract; 2021 Nov; 27(6):496-497. PubMed ID: 34768276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression.
    Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H
    Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.